Using a modified herpes virus to treat brain tumors in children
Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18.
This study is testing a new treatment using a specially designed virus to help kids with aggressive brain tumors by targeting the cancer cells while protecting healthy brain tissue, which could lead to fewer side effects than traditional treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10016247 on NIH RePORTER |
What this research studies
This research investigates a novel therapy using an engineered herpes simplex virus (oHSV) to target malignant brain tumors in children. The approach aims to selectively kill cancer cells while sparing normal brain tissue, potentially reducing the harmful side effects associated with traditional treatments like chemotherapy and radiation. By stimulating the immune system to respond to the tumor, this therapy could provide a safer and more effective treatment option for pediatric patients with aggressive brain tumors. The study builds on previous Phase I trials to assess the safety and efficacy of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with malignant cerebellar tumors who have limited treatment options.
Not a fit: Patients with non-malignant brain tumors or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment for children with malignant brain tumors, improving survival rates and quality of life.
How similar studies have performed: Previous trials using oncolytic viruses have shown promise in treating various cancers, suggesting potential success for this novel approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Friedman, Gregory K — University of Alabama at Birmingham
- Study coordinator: Friedman, Gregory K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.